Repare Therapeutics Inc - ESG Rating & Company Profile powered by AI
Alternative companies in the scoring industry group for Repare Therapeutics Inc are shown below. Detailed Sustainability assessment of Repare Therapeutics Inc can be accessed by logging in. This dashboard includes a Q&A section about Repare Therapeutics Inc.
Repare Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.1; made up of an environmental score of 4.0, social score of 4.8 and governance score of 6.4.
5.1
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 687 | Valbiotis SA | 5.2 | High |
| 687 | Zeria Pharmaceutical Co Ltd | 5.2 | High |
| 724 | Repare Therapeutics Inc | 5.1 | High |
| 724 | Catalyst Pharmaceuticals Inc | 5.1 | High |
| 724 | Adverum Biotechnologies Inc | 5.1 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Repare Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Repare Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Repare Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Repare Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Repare Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Repare Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Repare Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Repare Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Repare Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Repare Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Repare Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Repare Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Repare Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Repare Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Repare Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Repare Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Repare Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Repare Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Repare Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Repare Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Repare Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Repare Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Repare Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Repare Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Repare Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Repare Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Repare Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Repare Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Repare Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Repare Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Repare Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Repare Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Repare Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Repare Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Repare Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Repare Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Repare Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.